DK3277719T3 - Polypeptider - Google Patents
Polypeptider Download PDFInfo
- Publication number
- DK3277719T3 DK3277719T3 DK16713874.2T DK16713874T DK3277719T3 DK 3277719 T3 DK3277719 T3 DK 3277719T3 DK 16713874 T DK16713874 T DK 16713874T DK 3277719 T3 DK3277719 T3 DK 3277719T3
- Authority
- DK
- Denmark
- Prior art keywords
- polypeptider
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15162112 | 2015-03-31 | ||
PCT/EP2016/057021 WO2016156465A1 (en) | 2015-03-31 | 2016-03-31 | Polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3277719T3 true DK3277719T3 (da) | 2022-05-02 |
Family
ID=52811024
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16713874.2T DK3277719T3 (da) | 2015-03-31 | 2016-03-31 | Polypeptider |
DK22155238.3T DK4089113T3 (da) | 2015-03-31 | 2016-03-31 | Polypeptider |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK22155238.3T DK4089113T3 (da) | 2015-03-31 | 2016-03-31 | Polypeptider |
Country Status (17)
Country | Link |
---|---|
US (3) | US10633438B2 (da) |
EP (2) | EP4089113B1 (da) |
JP (1) | JP6895421B2 (da) |
KR (1) | KR102622281B1 (da) |
CN (1) | CN107454905B (da) |
AU (1) | AU2016239948B2 (da) |
BR (1) | BR112017020275A8 (da) |
CA (1) | CA2981096A1 (da) |
DK (2) | DK3277719T3 (da) |
EA (1) | EA035638B1 (da) |
ES (1) | ES2913200T3 (da) |
HK (1) | HK1250041A1 (da) |
IL (1) | IL254577B2 (da) |
MX (1) | MX2017012662A (da) |
NZ (1) | NZ734798A (da) |
SG (1) | SG11201706839YA (da) |
WO (1) | WO2016156465A1 (da) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1888641T3 (pl) * | 2005-05-18 | 2012-05-31 | Ablynx Nv | Białka wiążące albuminę surowicy |
IL254577B2 (en) * | 2015-03-31 | 2023-11-01 | Vhsquared Ltd | polypeptides |
EP3435982A1 (en) | 2016-03-31 | 2019-02-06 | VHsquared Limited | Compositions |
WO2018060453A1 (en) * | 2016-09-30 | 2018-04-05 | Vhsquared Limited | Compositions |
BR112019011702A2 (pt) * | 2016-12-14 | 2019-10-22 | Progenity Inc | tratamento de uma doença do trato gastrointestinal com um inibidor de il-12/il-23 liberado usando um dispositivo ingerível |
AU2017378393B2 (en) | 2016-12-14 | 2023-03-09 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a TNF inhibitor |
EP3581203A1 (en) * | 2018-06-11 | 2019-12-18 | Laboratoire Français du Fractionnement et des Biotechnologies | Antibodies with increased activity in the digestive tract |
EP3810095A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
US20230023414A1 (en) | 2018-11-19 | 2023-01-26 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
CN111499762B (zh) * | 2019-01-31 | 2022-04-26 | 四川大学华西医院 | 一种包含PDGFRβ特异性亲和体和TNFα的融合蛋白及其用途 |
US20230096620A1 (en) * | 2019-04-17 | 2023-03-30 | Millennium Pharmaceuticals, Inc. | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
US20220228121A1 (en) * | 2019-05-31 | 2022-07-21 | Trustees Of Tufts College | Cultured meat product with genetically modified cells |
WO2020254827A1 (en) | 2019-06-21 | 2020-12-24 | Vhsquared Limited | Polypeptides |
KR20220063148A (ko) | 2019-06-21 | 2022-05-17 | 소리소 파마슈티컬스 인크. | 조성물 |
JP2022538083A (ja) | 2019-06-21 | 2022-08-31 | ソリッソ ファーマシューティカルズ,インク. | ポリペプチド |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2024036194A1 (en) * | 2022-08-09 | 2024-02-15 | Proteintech Group, Inc. | Multivalent linkers used for antibody labeling |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0486526T3 (da) | 1989-08-07 | 1996-06-24 | Peptide Technology Ltd | Bindingsligander for tumornekrosefaktor |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever Nv | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US6670453B2 (en) | 1997-10-27 | 2003-12-30 | Unilever Patent Holdings B.V. | Multivalent antigen-binding proteins |
EP0954978B1 (en) | 1998-03-12 | 2011-11-30 | VHsquared Limited | New products comprising inactivated yeasts or moulds provided with active antibodies |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
EP1349945B1 (en) | 2000-12-13 | 2007-01-17 | Unilever N.V. | Method for the production of a heterologous protein by a fungus |
IL159177A0 (en) * | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
TWI327597B (en) | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
PT1944322E (pt) | 2002-07-19 | 2015-07-01 | Abbvie Biotechnology Ltd | Tratamento de distúrbios relacionados com tnf-alfa |
MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
JP2006520584A (ja) | 2002-11-08 | 2006-09-14 | アブリンクス エン.ヴェー. | 安定化単一ドメイン抗体 |
AU2003286003B2 (en) | 2002-11-08 | 2011-05-26 | Ablynx N.V. | Stabilized single domain antibodies |
US20060034845A1 (en) * | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
US20060034833A1 (en) | 2002-11-08 | 2006-02-16 | Els Beirnaert | Single domain antibodies directed against interferron-gamma and uses therefor |
CN102584997A (zh) * | 2002-11-08 | 2012-07-18 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子-α的单结构域抗体及其用途 |
US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
TWI439284B (zh) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療TNFα相關失調症之多重可變劑量療法 |
CN101039959A (zh) * | 2004-06-30 | 2007-09-19 | 杜门蒂斯有限公司 | 用于治疗炎性疾病的组合物和方法 |
PL1888641T3 (pl) | 2005-05-18 | 2012-05-31 | Ablynx Nv | Białka wiążące albuminę surowicy |
US20070042399A1 (en) | 2005-06-23 | 2007-02-22 | Imperial College Innovations Limited | Biological materials and uses thereof |
AU2006286563B2 (en) | 2005-08-30 | 2012-02-23 | Intrexon Actobiotics Nv | Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis |
WO2007048022A2 (en) | 2005-10-21 | 2007-04-26 | Alexion Pharmaceuticals, Inc. | Antibody-polypeptide fusion proteins and methods for producing and using same |
CA2634083A1 (en) | 2005-12-20 | 2007-06-28 | Arana Therapeutics Limited | Chimeric antibodies with part new world primate binding regions |
AU2007224631A1 (en) | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against IL-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
WO2008042067A2 (en) | 2006-09-28 | 2008-04-10 | Illumina, Inc. | Compositions and methods for nucleotide sequencing |
JP2010507624A (ja) | 2006-10-27 | 2010-03-11 | アブリンクス エン.ヴェー. | ポリペプチド及びタンパク質の鼻内送達 |
US20160031971A9 (en) | 2007-02-20 | 2016-02-04 | Tufts University | Methods and compositions with a recombinant neutralizing binding protein for treating toxin exposure |
JP2010518839A (ja) | 2007-02-21 | 2010-06-03 | アブリンクス エン.ヴェー. | 血管内皮増殖因子に指向性を有するアミノ酸配列、及び過度の及び/もしくは病的な血管形成又は血管新生を特徴とする症状及び疾患を治療するためにこれを含むポリペプチド |
US7807168B2 (en) | 2007-04-10 | 2010-10-05 | Vaccinex, Inc. | Selection of human TNFα specific antibodies |
WO2008144753A2 (en) | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Antibodies to tnf alpha and use thereof |
GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
JP5485152B2 (ja) | 2007-08-15 | 2014-05-07 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 単一特異性および多特異性抗体ならびに使用方法 |
EP2725035A1 (en) | 2007-10-02 | 2014-04-30 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
EP2215123A1 (en) | 2007-11-27 | 2010-08-11 | Ablynx N.V. | Immunoglobulin constructs |
DK2285408T3 (da) | 2008-06-05 | 2019-02-04 | Ablynx Nv | Aminosyresekvenser rettet mod kappeproteiner i et virus og polypeptider, der omfatter disse, til behandling af virussygdomme |
GB0815264D0 (en) | 2008-08-21 | 2008-09-24 | Syntaxin Ltd | Non-cytotoxic proteins |
WO2010045506A2 (en) | 2008-10-16 | 2010-04-22 | Kathleen Cogan Farinas | Sustained drug delivery system |
MX345226B (es) | 2008-10-29 | 2017-01-20 | Ablynx Nv | Formulaciones de moleculas de union a antigeno de dominio sencillo. |
CA2739352C (en) | 2008-10-29 | 2021-07-13 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
CL2010000019A1 (es) | 2010-01-11 | 2010-06-11 | Univ Chile | Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion. |
WO2011139629A2 (en) | 2010-04-26 | 2011-11-10 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
WO2011135040A1 (en) | 2010-04-30 | 2011-11-03 | F. Hoffmann-La Roche Ag | Fluorescent antibody fusion protein, its production and use |
CN103119062A (zh) | 2010-07-16 | 2013-05-22 | 埃博灵克斯股份有限公司 | 修饰的单结构域抗原结合分子及其应用 |
WO2012055030A1 (en) * | 2010-10-25 | 2012-05-03 | National Research Council Of Canada | Clostridium difficile-specific antibodies and uses thereof |
AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
AU2012237287B2 (en) | 2011-03-30 | 2016-09-08 | Ablynx Nv | Methods of treating immune disorders with single domain antibodies against TNF-alpha |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
CA3142288A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
KR102162413B1 (ko) | 2011-08-17 | 2020-10-07 | 글락소 그룹 리미티드 | 변형된 단백질 및 펩티드 |
CA2852874A1 (en) | 2011-10-19 | 2013-04-25 | Alexion Pharma Holding | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
GB2504139B (en) | 2012-07-20 | 2014-12-31 | Argen X Bv | Antibodies to highly conserved targets produced by the immunisation of Camelidae species |
DE102011121237A1 (de) | 2011-12-14 | 2013-06-20 | Universitätsklinikum Hamburg-Eppendorf | Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa |
DE102011121238A1 (de) | 2011-12-14 | 2013-06-20 | Universitätsklinikum Hamburg-Eppendorf | Einzeldomänen-antikörper gegen clostridium difficile toxine |
US9879093B2 (en) | 2011-12-20 | 2018-01-30 | Adaerata, Limited Partnershp | Single domain antibodies as inhibitors of PCSK9 |
JP6629069B2 (ja) | 2012-06-06 | 2020-01-15 | ゾエティス・エルエルシー | イヌ化抗ngf抗体およびその方法 |
EA028244B1 (ru) | 2012-08-13 | 2017-10-31 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА К PCSK9 C pH-ЗАВИСИМЫМИ ХАРАКТЕРИСТИКАМИ СВЯЗЫВАНИЯ |
US20140186365A1 (en) | 2013-01-03 | 2014-07-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn |
EP3062818B1 (en) | 2013-11-01 | 2019-09-11 | IBC Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
WO2015100409A2 (en) | 2013-12-26 | 2015-07-02 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein |
KR20160142849A (ko) | 2014-03-26 | 2016-12-13 | 셀 메디카 스위처란트 아게 | Tnf 알파에 대한 결합 구성원 |
US9546211B2 (en) | 2014-10-23 | 2017-01-17 | Singh Molecular Medicine, Llc | Single domain antibodies directed against TNF-alpha |
EP3237000A1 (en) | 2014-12-23 | 2017-11-01 | Pfizer Inc | Stable aqueous antibody formulation for anti tnf alpha antibodies |
WO2016156475A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b |
IL254577B2 (en) | 2015-03-31 | 2023-11-01 | Vhsquared Ltd | polypeptides |
WO2016156474A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a |
CA2981103A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
AU2016239949A1 (en) | 2015-03-31 | 2017-09-07 | Sorriso Pharmaceuticals, Inc. | Peptide construct having a protease-cleavable linker |
EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
WO2017125578A1 (en) | 2016-01-21 | 2017-07-27 | Vhsquared Limited | Polypeptides |
EP3435982A1 (en) * | 2016-03-31 | 2019-02-06 | VHsquared Limited | Compositions |
WO2018060453A1 (en) | 2016-09-30 | 2018-04-05 | Vhsquared Limited | Compositions |
-
2016
- 2016-03-31 IL IL254577A patent/IL254577B2/en unknown
- 2016-03-31 DK DK16713874.2T patent/DK3277719T3/da active
- 2016-03-31 SG SG11201706839YA patent/SG11201706839YA/en unknown
- 2016-03-31 CA CA2981096A patent/CA2981096A1/en active Pending
- 2016-03-31 AU AU2016239948A patent/AU2016239948B2/en active Active
- 2016-03-31 EA EA201792176A patent/EA035638B1/ru not_active IP Right Cessation
- 2016-03-31 ES ES16713874T patent/ES2913200T3/es active Active
- 2016-03-31 BR BR112017020275A patent/BR112017020275A8/pt active Search and Examination
- 2016-03-31 EP EP22155238.3A patent/EP4089113B1/en active Active
- 2016-03-31 NZ NZ734798A patent/NZ734798A/en unknown
- 2016-03-31 WO PCT/EP2016/057021 patent/WO2016156465A1/en active Application Filing
- 2016-03-31 EP EP16713874.2A patent/EP3277719B1/en active Active
- 2016-03-31 MX MX2017012662A patent/MX2017012662A/es unknown
- 2016-03-31 DK DK22155238.3T patent/DK4089113T3/da active
- 2016-03-31 CN CN201680020014.7A patent/CN107454905B/zh active Active
- 2016-03-31 KR KR1020177029482A patent/KR102622281B1/ko active IP Right Grant
- 2016-03-31 JP JP2018502328A patent/JP6895421B2/ja active Active
- 2016-09-22 US US15/273,353 patent/US10633438B2/en active Active
-
2018
- 2018-07-20 HK HK18109449.8A patent/HK1250041A1/zh unknown
-
2020
- 2020-03-17 US US16/821,287 patent/US20200317769A1/en not_active Abandoned
-
2023
- 2023-04-18 US US18/302,721 patent/US20230287098A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102622281B1 (ko) | 2024-01-08 |
EP3277719B1 (en) | 2022-03-16 |
IL254577B2 (en) | 2023-11-01 |
KR20170127021A (ko) | 2017-11-20 |
ES2913200T3 (es) | 2022-06-01 |
US10633438B2 (en) | 2020-04-28 |
US20200317769A1 (en) | 2020-10-08 |
MX2017012662A (es) | 2018-05-11 |
IL254577A0 (en) | 2017-11-30 |
CA2981096A1 (en) | 2016-10-06 |
EP4089113B1 (en) | 2023-12-13 |
EA035638B1 (ru) | 2020-07-20 |
JP2018514226A (ja) | 2018-06-07 |
BR112017020275A8 (pt) | 2023-01-31 |
AU2016239948A1 (en) | 2017-09-07 |
EP4089113A1 (en) | 2022-11-16 |
IL254577B1 (en) | 2023-07-01 |
AU2016239948B2 (en) | 2022-03-17 |
US20230287098A1 (en) | 2023-09-14 |
JP6895421B2 (ja) | 2021-06-30 |
SG11201706839YA (en) | 2017-09-28 |
EP3277719A1 (en) | 2018-02-07 |
HK1250041A1 (zh) | 2018-11-23 |
NZ734798A (en) | 2023-11-24 |
US20170002069A1 (en) | 2017-01-05 |
BR112017020275A2 (pt) | 2018-06-05 |
WO2016156465A1 (en) | 2016-10-06 |
DK4089113T3 (da) | 2024-02-05 |
CN107454905A (zh) | 2017-12-08 |
EA201792176A1 (ru) | 2018-02-28 |
CN107454905B (zh) | 2023-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3283625T3 (da) | Nukleasemedieret genomeditering | |
DK3331869T3 (da) | Muscarinagonister | |
DK3305788T3 (da) | Janus-kinase-hæmmer | |
DK3277719T3 (da) | Polypeptider | |
DK3331528T3 (da) | Muskarinagonister | |
DK3360890T3 (da) | Genterapi | |
DK3310450T3 (da) | Olie-vand-separator | |
DK3331529T3 (da) | Muskarinagonister | |
DK3270930T3 (da) | Præeklampsi | |
DK3292136T3 (da) | Penicillin-g-acylaser | |
DK3394281T3 (da) | Gærcelle | |
DE112015006486A5 (de) | Inkubationsrinne | |
DK3318308T3 (da) | Badmintonketsjer | |
DK3274482T3 (da) | Stenborsknop | |
DE112016005599A5 (de) | Strahlungsgrill | |
DE112015005898A5 (de) | Gurtschlossbringer | |
ES1140083Y (es) | Descompatactador tetrafunción | |
DE102015206660A8 (de) | Plattenaufteilanlage | |
DE112016001124A5 (de) | Spannschutz | |
FI11070U1 (fi) | Kantojyrsin | |
DE102015000551A8 (de) | Rotationszerstäuberturbine | |
DE102015226549B8 (de) | Hybridheizmodul | |
FI11139U1 (fi) | Piirikorttikokoonpano | |
FI11131U1 (fi) | Muuttajalaitejärjestely | |
ES1158483Y (es) | Lucy-clip |